Daily SPAC Update – March 17, 2025

by | Mar 17, 2025

Target Global and VenHub Fight Over Deal Termination. Hennessey Capital VI + Namib Minerals Deal Vote Set. 3 More SPAC Delistings.

Boardroom Alpha SPAC Resources
– Full SPAC Listing
– SPAC SEC Filings
– Boardroom Alpha IPO & SPAC Intelligence Platform (7-Day Trial)

Daily SPAC Update

SPAC DEAL & EXTENSION VOTES SET
HCVI – Hennessy Capital Investment Corp VI + Namib Minerals * DEAL VOTE SET: Apr 07, 2025 * trust $10.80

SPAC NEWS
DSAQ – DIRECT SELLING ACQUISITION CORP * Trust Update * trust $11.86
TGAAF – TARGET GLOBAL ACQUISITION I CORP * Deal Termination Dispute

SPAC DELISTINGS
GLST – GLOBAL STAR ACQUISITION INC * Delisting
BNIX – BANNIX ACQUISITION CORP * Delisting
PLAO – PATRIA LATIN AMERICAN OPPORTUNITY ACQUISITION CORP * Delisting

SPAC INVESTOR DECKS
BHAC – FOCUS IMPACT BH3 ACQUISITION CO * Investor Deck
SKGR – SK GROWTH OPPORTUNITIES CORP * Investor Deck

SEPARATE WARRANTS/RIGHTS
Mar 17: COLUMBUS ACQUISITION CORP (COLA)

YESTERDAY’S TOP SPAC GAINERS
1.46% ~ $ 11.10 | DMYY – DMY SQUARED TECHNOLOGY GROUP INC (Pre-Deal)
.47% ~ $ 10.62 | CCIX – CHURCHILL CAPITAL CORP IX (Pre-Deal)
.31% ~ $ 10.54 | IROH – IRON HORSE ACQUISITIONS CORP (Announced)
.29% ~ $ 10.33 | IBAC – IB ACQUISITION CORP (Pre-Deal)
.27% ~ $ 10.96 | AITR – AI TRANSPORTATION ACQUISITION CORP (Pre-Deal)

YESTERDAY’S TOP SPAC LOSERS
-9.76% ~ $ 3.93 | BOWN – BOWEN ACQUISITION CORP (Announced)
-1.96% ~ $ 12.01 | WINV – WINVEST ACQUISITION CORP (Announced)
-1.95% ~ $ 10.79 | IPXX – INFLECTION POINT ACQUISITION CORP II (Announced)
-1.19% ~ $ 11.61 | BNIX – BANNIX ACQUISITION CORP (Pre-Deal)
-.96% ~ $ 11.40 | FTII – FUTURETECH II ACQUISITION CORP (Announced)

LATEST SPAC IPO PERFORMANCE
Feb 27 | $ 10.05 | LOKV – Live Oak Acquisition Corp. V
Feb 27 | $ 10.05 | NHIC – NewHold Investment Corp. III
Feb 27 | $ 10.02 | FERA – Fifth Era Acquisition Corp I
Feb 26 | $ 10.04 | RAC – Rithm Acquisition Corp.

Recent Analysis

Daily SPAC Update – April 29, 2026

Collective Acquisition Corp. II (CAII) launched its $220 million IPO today, targeting high-potential sectors like technology and healthcare. In executive moves, Roger Bendelac was appointed CEO of both Drugs Made in America Acquisition Corp (DMAA) and Drugs Made in America Acquisition II Corp (DMII), with Saleem Elmasri as CFO. Meanwhile, General Purpose Acquisition Corp (GPAC) saw a significant decline of 22.9%, closing at $9.96, while Aimei Health Technology Co Ltd (AFJK) gained 2.7% to $46.12.

Daily SPAC Update – April 28, 2026

SPAC IPOs Look Stalled Again as Irenic’s $220M IPO Only Makes it Seven. Miluna Acquisition + CADV.AI Deal. Prophyte Extension Vote to Add 12 More Months.

Daily SPAC Update – April 20, 2026

Piermont Announces Deal with Tigerless Health. Climaterock sets extension vote. Horizon Space Extension Vote Today. Suma, TRG Latin America, and MOZAYYX Separate Trading.

Subscribe to Boardroom Alpha Newsletters

Subscribe to Boardroom Alpha's research to receive the latest on governance, SPACs, and people.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.